Delek Group Ltd. increased its stake in shares of ADMA Biologics Inc (NASDAQ:ADMA) by 102.5% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 118,539 shares of the biotechnology company’s stock after acquiring an additional 60,000 shares during the quarter. Delek Group Ltd.’s holdings in ADMA Biologics were worth $291,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in the stock. United Services Automobile Association bought a new stake in ADMA Biologics in the 4th quarter valued at about $27,000. Dimensional Fund Advisors LP bought a new stake in ADMA Biologics in the 4th quarter valued at about $34,000. Rhumbline Advisers boosted its holdings in ADMA Biologics by 50.5% in the 4th quarter. Rhumbline Advisers now owns 23,279 shares of the biotechnology company’s stock valued at $56,000 after purchasing an additional 7,810 shares during the period. Raymond James & Associates boosted its holdings in ADMA Biologics by 65.2% in the 4th quarter. Raymond James & Associates now owns 26,871 shares of the biotechnology company’s stock valued at $64,000 after purchasing an additional 10,610 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in ADMA Biologics by 14.4% in the 4th quarter. Geode Capital Management LLC now owns 276,930 shares of the biotechnology company’s stock valued at $661,000 after purchasing an additional 34,818 shares during the period. 56.60% of the stock is owned by institutional investors and hedge funds.

Shares of ADMA Biologics stock traded up $0.04 on Thursday, reaching $3.93. 323 shares of the stock were exchanged, compared to its average volume of 397,948. ADMA Biologics Inc has a one year low of $2.08 and a one year high of $6.96. The company has a current ratio of 6.32, a quick ratio of 4.92 and a debt-to-equity ratio of 1.11. The company has a market cap of $184.94 million, a PE ratio of -2.05 and a beta of 3.01.

A number of research firms have issued reports on ADMA. Maxim Group set a $12.00 price objective on shares of ADMA Biologics and gave the company a “buy adma” rating in a report on Thursday, December 20th. HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of ADMA Biologics in a report on Thursday, February 7th. Finally, Oppenheimer set a $13.00 price objective on shares of ADMA Biologics and gave the company a “buy adma” rating in a report on Thursday, December 20th. Seven equities research analysts have rated the stock with a buy rating, The stock has a consensus rating of “Buy” and an average price target of $10.42.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of US & international copyright & trademark legislation. The original version of this piece of content can be viewed at https://www.watchlistnews.com/adma-biologics-inc-adma-shares-bought-by-delek-group-ltd/2890334.html.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.

Featured Story: What do investors mean by earnings per share?

Want to see what other hedge funds are holding ADMA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ADMA Biologics Inc (NASDAQ:ADMA).

Institutional Ownership by Quarter for ADMA Biologics (NASDAQ:ADMA)

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.